TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Devendra Hiwase; Christopher Hahn; Elizabeth Ngoc Hoa Tran; Rakchha Chhetri; Anmol Baranwal; Aref Al-Kali; Kirsty Sharplin; Dariusz Ladon; Rachel Hollins; Patricia Greipp; Monika Kutyna; Hassan Alkhateeb; Talha Badar; Paul Wang; David M. Ross; Deepak Singhal; Naranie Shanmuganathan; Peter Bardy; Ashanka Beligaswatte; David Yeung; Mark R. Litzow; Abhishek Mangaonkar; Pratyush Giri; Cindy Lee; Angie Yong; Noemi Horvath; Nimit Singhal; Raghu Gowda; William Hogan; Naseema Gangat; Mrinal Patnaik; Kebede Begna; Ing S. Tiong; Andrew Wei; Sharad Kumar; Anna Brown; Hamish Scott; Daniel Thomas; Chung H. Kok; Ayalew Tefferi; Mithun Vinod Shah

doi:10.1182/blood.2022018236

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Devendra Hiwase
, Christopher Hahn
, Elizabeth Ngoc Hoa Tran
, Rakchha Chhetri
, Anmol Baranwal
, Aref Al-Kali
, Kirsty Sharplin
, Dariusz Ladon
, Rachel Hollins
, Patricia Greipp
, Monika Kutyna
, Hassan Alkhateeb
, Talha Badar
, Paul Wang
, David M. Ross
, Deepak Singhal
, Naranie Shanmuganathan
, Peter Bardy
, Ashanka Beligaswatte
, David Yeung

Mark R. Litzow, Abhishek Mangaonkar, Pratyush Giri, Cindy Lee, Angie Yong, Noemi Horvath, Nimit Singhal, Raghu Gowda, William Hogan, Naseema Gangat, Mrinal Patnaik, Kebede Begna, Ing S. Tiong, Andrew Wei, Sharad Kumar, Anna Brown, Hamish Scott, Daniel Thomas, Chung H. Kok, Ayalew Tefferi, Mithun Vinod Shah

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

Original language	English
Pages (from-to)	1087-1091
Number of pages	5
Journal	Blood
Volume	141
Issue number	9
DOIs	https://doi.org/10.1182/blood.2022018236
Publication status	Published or Issued - 2 Mar 2023

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2022018236

Cite this

Hiwase, D., Hahn, C., Tran, E. N. H., Chhetri, R., Baranwal, A., Al-Kali, A., Sharplin, K., Ladon, D., Hollins, R., Greipp, P., Kutyna, M., Alkhateeb, H., Badar, T., Wang, P., Ross, D. M., Singhal, D., Shanmuganathan, N., Bardy, P., Beligaswatte, A., ... Shah, M. V. (2023). TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood, 141(9), 1087-1091. https://doi.org/10.1182/blood.2022018236

@article{83e4c04e46e74230a0f2bc95f86e9532,

title = "TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype",

author = "Devendra Hiwase and Christopher Hahn and Tran, \{Elizabeth Ngoc Hoa\} and Rakchha Chhetri and Anmol Baranwal and Aref Al-Kali and Kirsty Sharplin and Dariusz Ladon and Rachel Hollins and Patricia Greipp and Monika Kutyna and Hassan Alkhateeb and Talha Badar and Paul Wang and Ross, \{David M.\} and Deepak Singhal and Naranie Shanmuganathan and Peter Bardy and Ashanka Beligaswatte and David Yeung and Litzow, \{Mark R.\} and Abhishek Mangaonkar and Pratyush Giri and Cindy Lee and Angie Yong and Noemi Horvath and Nimit Singhal and Raghu Gowda and William Hogan and Naseema Gangat and Mrinal Patnaik and Kebede Begna and Tiong, \{Ing S.\} and Andrew Wei and Sharad Kumar and Anna Brown and Hamish Scott and Daniel Thomas and Kok, \{Chung H.\} and Ayalew Tefferi and Shah, \{Mithun Vinod\}",

note = "Funding Information: This work was supported by Paul Calabresi Program in Clinical / Translational Research at Mayo Clinic ( K12CA090628 ), Leukemia Research Foundation New Investigator Award, Bridget Kiely Clinician Career Development in Transplant Research, and research funding by Astellas , Celgene , and Marker Therapeutics (M.V.S.); by a National Health and Medical Research Council (NHMRC)/Medical Research Future Fund (MRFF) Investigator Grant (MRF1195517), Cancer Australia, and Leukemia Foundation Australia (D.H.); by a NHMRC Investigator Grant (GNT2007739) (S.K.); and by a CSL Centenary Fellowship, Medical Research Futures Fund, and Leukemia-Lymphoma Translational Research Program funding (D.T.). Funding Information: The authors gratefully acknowledge the support of the South Australia Cancer Research Biobank (SACRB). ",

year = "2023",

month = mar,

day = "2",

doi = "10.1182/blood.2022018236",

language = "English",

volume = "141",

pages = "1087--1091",

journal = "Blood",

issn = "0006-4971",

number = "9",

}

Hiwase, D, Hahn, C, Tran, ENH, Chhetri, R, Baranwal, A, Al-Kali, A, Sharplin, K, Ladon, D, Hollins, R, Greipp, P, Kutyna, M, Alkhateeb, H, Badar, T, Wang, P, Ross, DM, Singhal, D, Shanmuganathan, N, Bardy, P, Beligaswatte, A, Yeung, D, Litzow, MR, Mangaonkar, A, Giri, P, Lee, C, Yong, A, Horvath, N, Singhal, N, Gowda, R, Hogan, W, Gangat, N, Patnaik, M, Begna, K, Tiong, IS, Wei, A, Kumar, S, Brown, A, Scott, H, Thomas, D, Kok, CH, Tefferi, A & Shah, MV 2023, 'TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype', Blood, vol. 141, no. 9, pp. 1087-1091. https://doi.org/10.1182/blood.2022018236

TY - JOUR

T1 - TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

AU - Hiwase, Devendra

AU - Hahn, Christopher

AU - Tran, Elizabeth Ngoc Hoa

AU - Chhetri, Rakchha

AU - Baranwal, Anmol

AU - Al-Kali, Aref

AU - Sharplin, Kirsty

AU - Ladon, Dariusz

AU - Hollins, Rachel

AU - Greipp, Patricia

AU - Kutyna, Monika

AU - Alkhateeb, Hassan

AU - Badar, Talha

AU - Wang, Paul

AU - Ross, David M.

AU - Singhal, Deepak

AU - Shanmuganathan, Naranie

AU - Bardy, Peter

AU - Beligaswatte, Ashanka

AU - Yeung, David

AU - Litzow, Mark R.

AU - Mangaonkar, Abhishek

AU - Giri, Pratyush

AU - Lee, Cindy

AU - Yong, Angie

AU - Horvath, Noemi

AU - Singhal, Nimit

AU - Gowda, Raghu

AU - Hogan, William

AU - Gangat, Naseema

AU - Patnaik, Mrinal

AU - Begna, Kebede

AU - Tiong, Ing S.

AU - Wei, Andrew

AU - Kumar, Sharad

AU - Brown, Anna

AU - Scott, Hamish

AU - Thomas, Daniel

AU - Kok, Chung H.

AU - Tefferi, Ayalew

AU - Shah, Mithun Vinod

N1 - Funding Information: This work was supported by Paul Calabresi Program in Clinical / Translational Research at Mayo Clinic ( K12CA090628 ), Leukemia Research Foundation New Investigator Award, Bridget Kiely Clinician Career Development in Transplant Research, and research funding by Astellas , Celgene , and Marker Therapeutics (M.V.S.); by a National Health and Medical Research Council (NHMRC)/Medical Research Future Fund (MRFF) Investigator Grant (MRF1195517), Cancer Australia, and Leukemia Foundation Australia (D.H.); by a NHMRC Investigator Grant (GNT2007739) (S.K.); and by a CSL Centenary Fellowship, Medical Research Futures Fund, and Leukemia-Lymphoma Translational Research Program funding (D.T.). Funding Information: The authors gratefully acknowledge the support of the South Australia Cancer Research Biobank (SACRB).

PY - 2023/3/2

Y1 - 2023/3/2

UR - https://www.scopus.com/pages/publications/85147307685

U2 - 10.1182/blood.2022018236

DO - 10.1182/blood.2022018236

M3 - Article

C2 - 36574363

AN - SCOPUS:85147307685

SN - 0006-4971

VL - 141

SP - 1087

EP - 1091

JO - Blood

JF - Blood

IS - 9

ER -

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this